Levin, Bruce <br/><br/>
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.  [electronic resource] 

 -  Clinical trials (London, England)  Aug 2011 
 - 398-407 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1740-7753 
<br/><br/><label>Standard No.: </label>10.1177/1740774511410582  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Clinical Trials, Phase II as Topic--methods<br/>Clinical Trials, Phase III as Topic--methods<br/>Computer Simulation<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Approval<br/>Early Termination of Clinical Trials<br/>Fibrinolytic Agents--administration & dosage<br/>Humans<br/>Multicenter Studies as Topic--methods<br/>Patient Selection<br/>Randomized Controlled Trials as Topic--methods<br/>Research Design<br/>Selection Bias<br/>Stroke--drug therapy<br/>Tenecteplase<br/>Tissue Plasminogen Activator--administration & dosage